Loading
A phase 1/2 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT06157827 by Nanjing Leads Biolabs Co.,Ltd, with 178 participants planned, started 2023-12-08. Conditions recorded: Advanced Neuroendocrine Carcinoma. Interventions recorded: LBL-024 for Injection, Etoposide Injection, Carboplatin Injection, Atezolizumab injection and Cisplatin injection.
Shares Opamtistomig, Nanjing Leads Biolabs, Neuroendocrine tumours and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/